Previous studies have shown that JAK2 inhibitors can ameliorate symptoms and reduce spleen size in chronic MPN (21), and JAK inhibitor monotherapy can induce transient responses in patients with post-MPN AML (22). The gene discussed is JAK2; the disease is myeloproliferative neoplasm.